Log in to your Inderes Free account to see all free content on this page.
OncoZenge
6.47 SEK
-3.58 %
Less than 1K followers
ONCOZ
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-3.58 %
+27.11 %
+2.54 %
+17.42 %
+72.53 %
+42.35 %
+24.42 %
-
-47.13 %
OncoZenge is a Swedish pharmaceutical company that develops treatments for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. The company's product candidate is undergoing further development after completing phase 2 studies to form the basis for application for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.
Read moreMarket cap
81.83M SEK
Turnover
322.59K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
18.2.
2026
Annual report '25
20.5.
2026
Interim report Q1'26
27.5.
2026
General meeting '26
All
Press releases
ShowingAll content types
OncoZenge Strengthens Advisory Board with Co-Inventor Dr. Torben Mogensen Ahead of Phase III Trial for BupiZenge™
BioStock: OncoZenge gearing up for phase III after a strong quarter
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio